Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination drug consisting of **heparin**, a highly sulfated glycosaminoglycan with potent anticoagulant properties, and **deoxycholic acid**, a bile acid used here as a conjugating agent to enhance oral bioavailability. The conjugate exhibits **amphiphilic properties** allowing it to be absorbed via the intestine when administered orally, bypassing the need for parenteral injection. This conjugate retains high anticoagulant activity (anti-FXa) and demonstrates antiangiogenic effects, attributed in part to size-controlled inhibition of growth factors such as VEGF. The primary therapeutic rationale is improved oral delivery of heparin for thromboprophylaxis (DVT, PE) and for antitumor applications due to antiangiogenic and cytostatic properties, as demonstrated in preclinical studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparin + deoxycholic acid.